SYNAPSE Microcurrent has been appointed onto a national framework agreement for innovative wound healing technologies. NHS Shared Business Services (NHS SBS) has awarded the company a two-year agreement after a competition involving more than 50 companies. In total, just four technologies were chosen. Accel-Heal builds on the long-established link between electrical current and the body's healing mechanisms. A compact device fitted with Synapse's patented micro-current technology, it is generally used as an adjunct treatment to compression bandages to significantly accelerate healing and improve patient comfort. John Gildersleeve, chief executive of Synapse, said: "The acceptance of Accel-Heal onto the framework agreement is an endorsement, not only of this remarkable product, but of the conviction we have demonstrated over a number of years in researching, developing and bringing to market a revolutionary new approach to the treatment of wounds; one that will not only have a dramatic effect on the quality of life for long-suffering chronic would patients, but also on costs."
Synapse wins place on wound healing framework
